Persistent neurological symptoms are among the most disabling manifestations of post-COVID-19 syndrome (PCS), yet the contribution of ongoing CNS immune activation remains uncertain. CSF studies including clinically relevant COVID-19 recovered control cohorts are scarce. In this prospective single-center study, we enro...
D. Erhart, L. Balz, I. Giotaki et al.· medRxiv· 0 citations
Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), established biomarkers of neuroaxonal injury and astroglial pathology, are frequently only assessed in blood, which limits conclusions regarding their origin. Bi-compartmental analyses of CSF and serum may help differentiate central or peripher...
D. Erhart, B. Fazeli, F. Bachhuber et al.· Neurobiology of Disease· 0 citations
Background and Objectives Reliable biomarkers for autoimmune encephalitis (AE) are limited, and emerging CSF markers are not incorporated into current diagnostic criteria. Prognostic tools remain insufficient, highlighting the need for biomarkers that support both early diagnosis and assessment of disease severity and...
F. Konen, E. Bucak, F. Bachhuber et al.· Neurology(R) neuroimmunology...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.